Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
48 stopped studies mapped to Primary Myelofibrosis and descendants · 88% state a reason
Over the 48 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06397313 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis(POTAMI-61) | Phase 2 | terminated | May 2, 2024 | Ryvu Therapeutics SA | Sponsor decision | Sponsor / business decision |
| NCT01962636 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for… | N/A | terminated | Oct 14, 2013 | Masonic Cancer Center, University of Minnesota | No longer a research question to answer. | Other (stated, no rule matched) |
| NCT03878199 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of… | Phase 1 / Phase 2 | terminated | Mar 18, 2019 | Ohio State University Comprehensive Cancer Center | The study was originally planned to assess four escalating DLs of ruxolitinib (upto 40 mg twice… | Enrollment / accrual |
| NCT04551066 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT04551053 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With… | Phase 3 | terminated | Sep 16, 2020 | Incyte Corporation | The study was terminated due to futility. | Efficacy / futility |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT01688011 | Connect® Myeloid Disease Registry | — | terminated | Sep 19, 2012 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT03755518 | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary…(FREEDOM) | Phase 3 | terminated | Nov 28, 2018 | Celgene | Slow accrual. | Enrollment / accrual |
| NCT00522990 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias | Phase 1 / Phase 2 | terminated | Aug 30, 2007 | Astex Pharmaceuticals, Inc. | Recommended Phase II dose determined | Other (stated, no rule matched) |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04629651 | Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative… | Phase 1 / Phase 2 | withdrawn | Nov 16, 2020 | Case Comprehensive Cancer Center | PI discretion | Other (stated, no rule matched) |
| NCT04480086 | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With… | Phase 1 | terminated | Jul 21, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera… | Phase 1 | withdrawn | May 21, 2021 | Lynk Pharmaceuticals Co., Ltd | sponsor decision | Sponsor / business decision |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | Phase 1 / Phase 2 | terminated | Apr 29, 2021 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT01014546 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | Phase 1 | terminated | Nov 17, 2009 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT04354727 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | Phase 1 / Phase 2 | withdrawn | Apr 21, 2020 | Ascentage Pharma Group Inc. | Sponsor decision | Sponsor / business decision |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | Phase 2 | terminated | Oct 6, 2017 | University of Utah | Slow accrual | Enrollment / accrual |
| NCT02055781 | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and…(PAC326) | Phase 3 | terminated | Feb 5, 2014 | CTI BioPharma | not stated | Not stated |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | Phase 1 | withdrawn | Feb 25, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | Phase 3 | terminated | Jan 23, 2013 | CTI BioPharma | not stated | Not stated |
| NCT03121599 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | N/A | terminated | Apr 20, 2017 | Hamad Medical Corporation | Delayed study materials, poor recruitment | Enrollment / accrual |
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With… | Phase 2 | terminated | Apr 7, 2016 | M.D. Anderson Cancer Center | Terminated Per PIs request due to low accrual | Enrollment / accrual |
| NCT03718143 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis | Phase 2 | terminated | Oct 24, 2018 | NYU Langone Health | Safety concerns | Safety / toxicity |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT02871323 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Phase 1 | withdrawn | Aug 18, 2016 | Northwestern University | PI decided to withdraw the study after it opened for enrollment but before any patients were… | Enrollment / accrual |
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera… | Phase 2 | withdrawn | Aug 13, 2019 | M.D. Anderson Cancer Center | "Company is in a process of being taken over by another pharma and the new one has different ideas… | Sponsor / business decision |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated…(POE07-01) | Phase 1 | terminated | Feb 27, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Lack of accrual | Enrollment / accrual |
| NCT02564536 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk… | Phase 1 | withdrawn | Sep 30, 2015 | Washington University School of Medicine | Lack of funding following full FDA clinical hold | Funding |
| NCT02805868 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential… | Early Phase 1 | withdrawn | Jun 20, 2016 | Northwestern University | Funding | Funding |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host… | Phase 1 | withdrawn | Aug 19, 2015 | City of Hope Medical Center | The study design was revised so a new protocol will be opened. | Other (stated, no rule matched) |
| NCT02663648 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | — | withdrawn | Jan 26, 2016 | Shandong University | No eligible patient was enrolled. | Enrollment / accrual |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS,… | Phase 1 / Phase 2 | suspended | Sep 29, 2010 | Humanigen, Inc. | KaloBios to Wind Down Operations | Other (stated, no rule matched) |
| NCT01291784 | Anti-TGF-beta Therapy in Patients With Myelofibrosis | Phase 1 | terminated | Feb 8, 2011 | John Mascarenhas | Early termination when the drug was no longer made available by the pharmaceutical company due to… | Sponsor / business decision |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an… | Phase 2 | terminated | Oct 27, 2006 | The Emmes Company, LLC | Study stopped because of toxicity concerns. | Safety / toxicity |
| NCT01558778 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem… | N/A | withdrawn | Mar 20, 2012 | Roswell Park Cancer Institute | device not available | Other (stated, no rule matched) |
| NCT00522574 | A Safety Study of XL019 in Adults With Myelofibrosis | Phase 1 | terminated | Aug 29, 2007 | Exelixis | Due to emerging safety data | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials